Eleven Biotherapeutics traded at $0.58 this Friday March 4th, decreasing $0.01 or 1.76 percent since the previous trading session. Looking back, over the last four weeks, Eleven Biotherapeutics lost 20.94 percent. Over the last 12 months, its price fell by 75.95 percent. Looking ahead, we forecast Eleven Biotherapeutics to be priced at 0.57 by the end of this quarter and at 0.52 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Amgen 253.07 1.99 0.79% 9.46%
Bayer 54.30 0.74 1.38% 13.46%
Bristol-Myers Squibb 74.50 -0.03 -0.04% 8.03%
Corcept Therapeutics 26.79 -1.28 -4.56% 31.00%
Eli Lilly 310.84 -3.10 -0.99% 13.98%
Merck & Co 90.81 0.21 0.23% 15.20%
Pfizer 50.02 0.27 0.54% -0.79%
Rigel Pharmaceuticals 1.55 -0.02 -0.96% -57.79%
Roche Holding 315.65 -2.25 -0.71% -14.69%
Intrexon 2.39 -0.23 -8.78% -59.49%
X T L Biopharmaceuticals 1.62 -0.09 -5.02% -55.50%
Ziopharm Oncology 1.85 -0.10 -5.13% 10.12%

Indexes Price Day Year
USND 13176 47.47 0.36% -10.10%
US2000 2029 7.95 0.39% -6.79%

Eleven Biotherapeutics
Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company with a protein engineering platform, called AMP-Rx, that the Company apply to the discovery and development of protein therapeutics to treat diseases of the eye. The Companys therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to rationally design and engineer proteins to modulate the effects of cytokines. The Companys advanced product candidate is EBI-005, which it designed, engineered and generated using its AMP-Rx platform and is developing as a topical treatment for dry eye disease and allergic conjunctivitis. The Companys EBI-005 program is based on the role that elevated levels of the inflammatory cytokine interleukin-1, or IL-1, play in the initiation and maintenance of the inflammation and pain associated with dry eye disease and the redness and itching associated with allergic conjunctivitis.